Kuala Lumpur, July 2nd 2013 The ANRS International VISCONTI Post Treatment Controller Cohort.

Slides:

Advertisements

Similar presentations

Adherence to HCV Therapy: Relation with Virologic Outcomes and Changes in Adherence Over Time Vincent Lo Re, MD, MSCE V. Teal, R. Localio, V. Amorosa,

Advertisements

Hopital Pitié Salpérière

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV.

1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.

ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.

T follicular helper cells in HIV infection

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

Natural and induced control of HIV infection: differences and similarities VISCONTI Study Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales.

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

Dr Ayman Johargy ADENOVIRIDAE 3 rd Year Medicine Clinical Microbiology 2 nd Semester.

EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

INTERACTION BETWEEN VIRUSES AND HOST CELLS Dr AYMAN JOHARGY 3 rd Year Medicine Clinical Microbiology 2 nd Semester Lecture 4 3 rd Year Medicine Clinical.

2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,

Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,

Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

HIV Cellular Pathogenesis III

HIV Care Continuum, District 8- 2 Southwest (Albany), Georgia, 2012.

C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.

Naive CD4 T lymphocytes and recent thymic emigrants, 15 or more years after perinatal HIV infection The ANRS-EP38-IMMIP study Stéphane Blanche, Daniel.

HIV acquisition after arrival in France among sub-Saharan African migrants living with HIV in Paris area. Estimations from the ANRS PARCOURS.

1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.

The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.

Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.

PhD We knew nothing about the set-point viral loads. What was unknown about HIV-1 infection before this paper was published in 2007? 1.Virus density.

Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.

Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Immune reconstitution Anjie Zhen, PhD

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.

Time to HAART Resume after Structured Treatment Interruption is Strongly Associated with HIV DNA Level in PBMC at Interruption: Results of the ANRS 116.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Long-term clinical and viro-immunologic outcomes of post-treatment controllers (PTCs) in the ANRS-VISCONTI study Laurent HOCQUELOUX, MD Orléans’ Regional.

2 3 Population : 6,934,169 inhabitants 6 Sanitary regions UNAIDS (2014) - HIV prevalence : 2.5% = 110,000 PLHIV - Higher prevalence in southern regions.

Treatment-Naïve Adults

Catherine K. Koofhethile 21st IAS July,2016 Durban, SA

RAL + MVC + DRV/r + TDF-FTC

Accounting for uncertainty in the timing of seroconversion in combined models for pre- and post-treatment CD4 counts in HIV-patients Oliver Stirrup, Andrew.

and HIV Controllers Kuala Lumpur, 2nd July 2013

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Validating Definitions of Antiretroviral Treatment Failure in Malawi

Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda

? Neutralizing Antibodies: Research pathways in 2013 and beyond

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

EAC for children.

Switch to LPV/r monotherapy

Keep control: Elite and post-treatment controllers

INTRODUCTION OBJECTIVES METHODS RESULTS DISCUSSION

Presentation transcript:

Kuala Lumpur, July 2nd 2013 The ANRS International VISCONTI Post Treatment Controller Cohort

OBJECTIVES To build an international cohort of Post Treatment Controllers in order to : – Uncover mechanisms underlying viral control, i.e. HIV remission – Identify predictive markers associated with viral control after treatment interruption Main Outcome : To identify patients in whom HAART could be safely interrupted

To increase the number of cases: – To describe epidemiological and clinical characteristics of PTC Age, sex, PHI, Time of treatment initiation, treatment duration, ARV combinations used, transmission group… – To describe Virological and Immunological characteristics Analyse and quantification of the cellular and anatomical reservoirs Viral properties and interactions between viral and cellular proteins Innate and adaptive immunity, antibody response…. To Compare to other cohorts of patients at different stages of HIV infection: PHI, HIV controllers, Chronic patients, patients on HAART…

Methodology Inclusion criteria – Treatment initiation with VL >2000 HIV-RNA copies/ml, whatever the timing of infection – Treatment for more than 12 months – Viral control after Treatment interruption below 400 copies/ml for at least 12 months Data collected once a year

General organisation Funded and organized : ANRS – International Steering Committee – International Scientific Committee – PI : Asier Saez-Cirion and Laurent Hocqueloux International recruitment: Two levels of inclusion 1 – with Clinical and epidemiological data 2 – with Clinical and epidemiological data + BIOBANK CONTACT :